Amundi Pioneer Asset Management Inc. lessened its holdings in Shire PLC (NASDAQ:SHPG) by 40.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,700 shares of the biopharmaceutical company’s stock after selling 34,699 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in Shire were worth $7,864,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of SHPG. Harding Loevner LP boosted its holdings in Shire by 18,894.4% in the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after acquiring an additional 126,865,607 shares in the last quarter. Third Point LLC acquired a new stake in Shire in the third quarter worth about $183,768,000. Boston Partners boosted its holdings in Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after acquiring an additional 886,572 shares in the last quarter. ING Groep NV boosted its holdings in Shire by 9,043.1% in the fourth quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock worth $81,366,000 after acquiring an additional 518,800 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in Shire by 26,182.4% in the third quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after acquiring an additional 472,592 shares in the last quarter. 19.75% of the stock is owned by institutional investors and hedge funds.
Several brokerages have weighed in on SHPG. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a report on Wednesday, March 7th. BidaskClub downgraded Shire from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. ValuEngine downgraded Shire from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. SunTrust Banks decreased their target price on Shire to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Finally, Royal Bank of Canada set a $192.00 target price on Shire and gave the stock a “buy” rating in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $204.00.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.19% and a net margin of 28.17%. The company had revenue of $4.14 billion during the quarter. During the same period in the previous year, the firm posted $3.37 earnings per share. The company’s revenue was up 8.9% compared to the same quarter last year. equities research analysts predict that Shire PLC will post 15.23 EPS for the current fiscal year.
The business also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be issued a $0.8937 dividend. The ex-dividend date is Thursday, March 8th. This is an increase from Shire’s previous semiannual dividend of $0.15. This represents a yield of 1.33%. Shire’s payout ratio is presently 7.47%.
COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Holdings Trimmed by Amundi Pioneer Asset Management Inc.” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/03/19/shire-plc-shpg-holdings-trimmed-by-amundi-pioneer-asset-management-inc.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.